A Phase 1 Study of CX1003 (Kanitinib) in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily
inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor
receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor
activity of CX1003 in patients with refractory advanced or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Konruns Pharmaceutical Co., Ltd.
Collaborators:
Beijing Tongren Hospital National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College West China Hospital